Treatment of multiple sclerosis (MS) and other demyelinating conditions using lofepramine in combination with L-phenylalanine, tyrosine or tryptophan and possibly a vitamin B12 compound
OwnerCari Loderinventor
Life of this patent
Estimating the term…
Abstract
The use of a combination of a tricyclic or tetracyclic antidepressant, a serotonin reuptake inhibitor, or a monoamine oxidase inhibitor with a neurotransmitter-inducing or precursor compound is proposed in the preparation of medication for the treatment or prevention of multiple sclerosis or other demyelinating conditions. For use in treatment to ameliorate the effects of a demyelinating condition, a daily regime is proposed of from 10 to 220 mg lofepramine and from 100 mg to 5 g of L-phenylalanine, optionally supplemented with injections of vitamin B.sub.12.
Claims14
A method of treating or preventing nerve damage caused by multiple sclerosis, comprising administering to a patient in need thereof a combination of lofepramine, in an amount ranging from 10 mg to 220 mg per day and L-phenylalanine, in an amount of from about 100 mg to 5 g per day.
A method of treating or preventing multiple sclerosis, comprising co-administering to a patient in need thereof lofepramine, in an amount ranging from 10 mg to 220 mg per day and L-phenylalanine, in an amount of from about 100 mg to 5 g per day.
A package, comprising a unit dose of from 10-220 mg lofepramine and a unit dose of from 100 mg to 5 g of L-phenylalanine.
A composition, comprising a unit dosage form of 25-100 mg lofepramine and 400-600 mg L-phenylalanine.
Dependencies are inferred from the claim text.